BioXcel Therapeutics, Inc. financial data

Symbol
BTAI on Nasdaq
Industry
Pharmaceutical Preparations
Location
555 Long Wharf Drive, New Haven, CT
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 28, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 216 % -42.2%
Quick Ratio 6.87 % +13.4%
Debt-to-equity -172 % +87.6%
Return On Equity 73.3 % -96.1%
Return On Assets -101 % +30%
Operating Margin -2.97K % +76.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.49M shares -82.1%
Common Stock, Shares, Outstanding 3.1M shares +65.8%
Entity Public Float 41.3M USD -69.4%
Common Stock, Value, Issued 49K USD +63.3%
Weighted Average Number of Shares Outstanding, Basic 2.54M shares +39.2%
Weighted Average Number of Shares Outstanding, Diluted 2.54M shares +39.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2.27M USD +64.2%
Research and Development Expense 30.4M USD -63.9%
Costs and Expenses 69.5M USD -59.9%
Operating Income (Loss) -67.2M USD +60.9%
Net Income (Loss) Attributable to Parent -59.6M USD +66.7%
Earnings Per Share, Basic -23.5 USD/shares +76.1%
Earnings Per Share, Diluted -23.5 USD/shares +76.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 29.9M USD -54.2%
Inventory, Net 679K USD -65.9%
Other Assets, Current 1.44M USD -30.7%
Assets, Current 37.4M USD -48.2%
Property, Plant and Equipment, Net 475K USD -39.4%
Operating Lease, Right-of-Use Asset 382K USD -44.5%
Other Assets, Noncurrent 87K USD 0%
Assets 38.3M USD -48%
Accounts Payable, Current 16M USD +17.1%
Employee-related Liabilities, Current 35K USD -78.5%
Accrued Liabilities, Current 5.76M USD -53.6%
Liabilities, Current 22.2M USD -18.5%
Operating Lease, Liability, Noncurrent 65K USD -85.2%
Liabilities 131M USD +0.94%
Retained Earnings (Accumulated Deficit) -650M USD -10.1%
Stockholders' Equity Attributable to Parent -93.1M USD -64.8%
Liabilities and Equity 38.3M USD -48%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.7M USD +66.2%
Net Cash Provided by (Used in) Financing Activities 26.6M USD +10.3%
Common Stock, Shares Authorized 200M shares +100%
Common Stock, Shares, Issued 3.1M shares +65.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 8.92M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 29.9M USD -54.2%
Deferred Tax Assets, Valuation Allowance 192M USD +10.6%
Operating Lease, Liability 439K USD -44.1%
Depreciation 309K USD -2.83%
Lessee, Operating Lease, Liability, to be Paid 456K USD -45.5%
Property, Plant and Equipment, Gross 1.98M USD 0%
Operating Lease, Liability, Current 374K USD +8.09%
Lessee, Operating Lease, Liability, to be Paid, Year Two 65K USD -83.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 391K USD +2.63%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 17K USD -66.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 65K USD -83.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 557M USD +4.3%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 600K USD +205%
Share-based Payment Arrangement, Expense 6.16M USD -66.9%
Interest Expense 13.6M USD +17.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%